RUBY-3 is being conducted to determine if a new investigational drug, povetacicept, is safe and potentially beneficial for people with primary membranous nephropathy.
Investigational means that povetacicept is still being evaluated and is not approved by health authority (e.g., the United States Food and Drug Administration (FDA)) for primary membranous nephropathy or another condition.
Additional information is available at RUBY-3 ClinicalTrials.gov.